Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase-positive non-small cell lung cancer.
作者信息
Gupta Neeraj, Hanley Michael J, Sinha Vikram
机构信息
Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
出版信息
Br J Clin Pharmacol. 2022 Aug;88(8):3922-3923. doi: 10.1111/bcp.15322. Epub 2022 Mar 29.
Abstract
摘要
相似文献
1
Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase-positive non-small cell lung cancer.布加替尼用于间变性淋巴瘤激酶阳性非小细胞肺癌给药的药代动力学分析及临床证据
Br J Clin Pharmacol. 2022 Aug;88(8):3922-3923. doi: 10.1111/bcp.15322. Epub 2022 Mar 29.
2
Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.布加替尼和劳拉替尼：它们对非小细胞肺癌中 ALK 抑制剂的影响，重点关注耐药突变和中枢神经系统转移。
Jpn J Clin Oncol. 2021 Jan 1;51(1):37-44. doi: 10.1093/jjco/hyaa192.
3
Brigatinib: New-generation ALK inhibitor for nonsmall cell lung cancer.布加替尼：新一代针对非小细胞肺癌的 ALK 抑制剂。
Curr Probl Cancer. 2019 Dec;43(6):100477. doi: 10.1016/j.currproblcancer.2019.03.005. Epub 2019 May 6.
4
Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.布加替尼与其他第二代间变性淋巴瘤激酶抑制剂作为深度表型分析的间变性淋巴瘤激酶阳性非小细胞肺癌的初始治疗比较：ABP 试验研究方案。
BMC Cancer. 2021 Jun 28;21(1):743. doi: 10.1186/s12885-021-08460-w.
5
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.一名对布加替尼产生获得性耐药的ALK阳性肺癌患者中存在的复合L1196M/G1202R ALK突变也导致对劳拉替尼的原发性耐药。
J Thorac Oncol. 2019 Nov;14(11):e257-e259. doi: 10.1016/j.jtho.2019.06.028.
6
Pharmacokinetically-guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients.基于药代动力学的剂量调整以提高布加替尼在非小细胞肺癌患者中的疗效。
Br J Clin Pharmacol. 2022 Feb;88(4):1930-1934. doi: 10.1111/bcp.15088. Epub 2021 Oct 7.
7
Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.ALK 阳性非小细胞肺癌患者接受布加替尼早期准入项目治疗的实际治疗持续时间。
Future Oncol. 2020 May;16(15):1031-1041. doi: 10.2217/fon-2019-0849. Epub 2020 Apr 27.
8
Brigatinib-induced tuberculosis reactivation: A case report.布加替尼致结核再激活：1 例报告。
Curr Probl Cancer. 2021 Dec;45(6):100738. doi: 10.1016/j.currproblcancer.2021.100738. Epub 2021 Apr 10.
9
ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.ALTA-2 研究：布加替尼治疗阿来替尼或塞瑞替尼治疗后进展的 ALK 阳性晚期非小细胞肺癌患者的 II 期研究。
Future Oncol. 2021 May;17(14):1709-1719. doi: 10.2217/fon-2020-1119. Epub 2021 Feb 11.
10
Brigatinib is a cost-effective treatment in first-line anaplastic lymphoma kinase mutation-positive (ALK + ) advanced non-small cell lung cancer (NSCLC) with brain metastases.布加替尼是一线间变性淋巴瘤激酶突变阳性（ALK+）且伴有脑转移的晚期非小细胞肺癌（NSCLC）的一种具有成本效益的治疗方法。
J Oncol Pharm Pract. 2022 Apr;28(3):691-694. doi: 10.1177/10781552211073468. Epub 2022 Jan 7.
本文引用的文献
1
Pharmacokinetically-guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients.基于药代动力学的剂量调整以提高布加替尼在非小细胞肺癌患者中的疗效。
Br J Clin Pharmacol. 2022 Feb;88(4):1930-1934. doi: 10.1111/bcp.15088. Epub 2021 Oct 7.
2
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.真实世界中，布加替尼治疗预处理 ALK+转移性非小细胞肺癌患者的疗效。
Lung Cancer. 2021 Jul;157:9-16. doi: 10.1016/j.lungcan.2021.05.017. Epub 2021 May 24.
3
Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Exposure-Response Analyses of Pivotal ALTA Study.布加替尼在间变性淋巴瘤激酶阳性非小细胞肺癌中的剂量合理性：关键性 ALTA 研究的暴露-反应分析。
CPT Pharmacometrics Syst Pharmacol. 2020 Dec;9(12):718-730. doi: 10.1002/psp4.12569.
4
Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer.布加替尼在健康志愿者和癌症患者中的群体药代动力学。
Clin Pharmacokinet. 2021 Feb;60(2):235-247. doi: 10.1007/s40262-020-00929-4.
5
Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.ALK 阳性非小细胞肺癌患者接受布加替尼早期准入项目治疗的实际治疗持续时间。
Future Oncol. 2020 May;16(15):1031-1041. doi: 10.2217/fon-2019-0849. Epub 2020 Apr 27.
6
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).布加替尼在序贯 ALK 抑制剂治疗后的 ALK 阳性晚期非小细胞肺癌患者中的应用：一项多中心真实世界研究（BRIGALK 研究）。
Lung Cancer. 2019 Oct;136:109-114. doi: 10.1016/j.lungcan.2019.08.010. Epub 2019 Aug 14.
7
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.布加替尼与克唑替尼用于治疗间变性淋巴瘤激酶阳性的非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25.
8
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.布加替尼治疗克唑替尼耐药间变性淋巴瘤激酶阳性非小细胞肺癌患者的随机、多中心 II 期临床试验。
J Clin Oncol. 2017 Aug 1;35(22):2490-2498. doi: 10.1200/JCO.2016.71.5904. Epub 2017 May 5.
9
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.布加替尼在间变性淋巴瘤激酶重排的非小细胞肺癌和其他恶性肿瘤中的活性和安全性：一项单臂、开放标签、1/2 期试验。
Lancet Oncol. 2016 Dec;17(12):1683-1696. doi: 10.1016/S1470-2045(16)30392-8. Epub 2016 Nov 8.
Zotero 插件